Calithera Biosciences, an early-stage biotech developing a drug platform that inhibits tumor metabolism, raised $80 million by offering 8 million shares (upsized from 6 million) at $10, below the range of $13 to $15. Calithera Biosciences plans to list on the NASDAQ under the symbol CALA. Calithera Biosciences initially filed confidentially on 7/25/2014. Citi and Leerink Partners acted as lead managers on the deal.
